Adicet Bio (ACET) Accounts Payables (2017 - 2026)
Adicet Bio (ACET) posted quarterly Accounts Payables of $2.9 million for Q1 2026, down 33.48% year-over-year from $4.4 million in Q1 2025, and down 38.19% quarter-over-quarter from $4.7 million in Q4 2025.
Adicet Bio (ACET) Accounts Payables (2017 - 2026) Analysis & Trends
Adicet Bio's Accounts Payables history runs 10 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 33.48% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 33.48% YoY), while the FY2025 annual figure was $4.7 million, down 1.88% from the prior year.
- Accounts Payables for Q1 2026 stood at $2.9 million, down from $4.7 million in the prior quarter.
- The five-year high for Accounts Payables was $4.8 million in Q4 2024, with the low at $1.9 million in Q2 2024.
- The 5-year median for Accounts Payables is $3.5 million (2022), against an average of $3.6 million.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables jumped 98.23% in 2022, then sank 40.4% in 2023.
- Adicet Bio's Accounts Payables stood at $4.4 million in 2022, then tumbled by 40.4% to $2.6 million in 2023, then soared by 84.0% to $4.8 million in 2024, then slipped by 1.88% to $4.7 million in 2025, then slumped by 38.19% to $2.9 million in 2026.
- Business Quant data shows ACET's Accounts Payables at $2.9 million in Q1 2026, $4.7 million in Q4 2025, and $4.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Adicet Bio | 98.21 Mn | -19.98 Mn | - | 3.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.59 Mn |
| Mar 31, 2026 | 2.93 Mn |
| Dec 31, 2025 | 4.74 Mn |
| Sep 30, 2025 | 4.29 Mn |
| Jun 30, 2025 | 3.29 Mn |
| Mar 31, 2025 | 4.40 Mn |
| Dec 31, 2024 | 4.83 Mn |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 2.54 Mn |
| Dec 31, 2023 | 2.63 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 3.12 Mn |
| Mar 31, 2023 | 2.75 Mn |
| Dec 31, 2022 | 4.40 Mn |
| Sep 30, 2022 | 4.57 Mn |
| Jun 30, 2022 | 4.15 Mn |
| Mar 31, 2022 | 3.47 Mn |
| Dec 31, 2021 | 3.26 Mn |
| Sep 30, 2021 | 4.63 Mn |